Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...

Biohaven (NYSE:BHVN – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd.The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts ...

Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...

BHV-8000 from Biohaven Pharmaceuticals Inc. is a dual, brain-penetrant, oral small molecule that is highly selective against TYK2 and JAK1 enzymes, which are essential enzymes to the inflammatory ...

Biohaven (BHVN) announced that it will present 13 abstracts at the 2025 American Academy of Neurology, AAN, Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California.

Swiss National Bank raised its stake in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 12.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 154,800 ...

SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN ...

American Century Companies has boosted its stake in Biohaven (BHVN) by 9.5% during Q4, ETF Daily News reports, citing a recent SEC filing. The firm owned 558,761 shares of Biohaven after ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...